<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278393</url>
  </required_header>
  <id_info>
    <org_study_id>NU360</org_study_id>
    <nct_id>NCT02278393</nct_id>
  </id_info>
  <brief_title>A Clinical Study for Evaluating the Safety of a Plant Sterol-enriched Fermented Dairy Product in Japanese Healthy Adults</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE SAFETY OF EXCESSIVE CONSUMPTION OF PLANT STEROL-ENRICHED FERMENTED DAIRY PRODUCT OVER A 4-WEEK PERIOD IN JAPANESE HEALTHY ADULTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Japan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danone Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the safety of excessive consumption of plant sterol-enriched fermented dairy
      product over a 4-week period in Japanese healthy adults
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>Number of subjects with at least one adverse event by study group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>Number of adverse events by study group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>Descriptive statistics for systolic and diastolic blood pressure, heart rate and BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>To assess the change for systolic and diastolic blood pressure, heart rate and BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory measurements</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>Descriptive statistics for Haematology parameters, liver/kidney/muscle function parameters, carbohydrate metabolism parameters, lipids, minerals, proteins and electrolytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory measurements</measure>
    <time_frame>From baseline to 6 weeks (4-week consumption + 2-week follow-up periods)</time_frame>
    <description>To assess the change for Haematology parameters, liver/kidney/muscle function parameters, carbohydrate metabolism parameters, lipids, minerals, proteins and electrolytes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>1-Fermented Dairy Product with Phytosterols (test)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one arm active = 3 bottles of test product/day with 1,6g of phytosterols each</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2-Fermented dairy Product with No Phytosterols (control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one arm control product= 3 bottles test productl/day with no Phytosterols</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1-Fermented Dairy Product with Phytosterols (test)</intervention_name>
    <description>1- 3 bottles of test product/day</description>
    <arm_group_label>1-Fermented Dairy Product with Phytosterols (test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2-Fermented dairy Product with No Phytosterols (control)</intervention_name>
    <description>2-3 bottles of control product/day</description>
    <arm_group_label>2-Fermented dairy Product with No Phytosterols (control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be checked at the inclusion visit (V1) :

          -  II 01: Male/female subject, aged from 20 to 55 years (bounds included).

          -  II 02: Subject with body mass index (BMI) between 18.5 kg/m2 (bound included) and 30
             kg/m2 (bound excluded).

          -  II 03: Subject with LDL-cholesterol plasma level under 140 mg/dL (3.6 mmol/L) (bound
             excluded).

          -  II 04: Subject with triglycerides under 200 mg/dL (2.3 mmol/L) (bound included).

          -  II 05: Non hypertensive subject defined with Systolic Blood Pressure (SBP) &lt;140mmHg
             and Diastolic Blood Pressure (DBP) &lt;90 mmHg.

          -  II 06: Subject agreeing not to consume any supplements/excessive plant sterols and
             plant stanols in any form during the study period.

          -  II 07: If of childbearing potential, female subject must be using or complying with
             one of the following medically approved methods of contraception such as, but not
             exclusively:

          -  Oral birth control pills (at least 1 full monthly cycle prior to study product
             administration);

          -  Intra-uterine device (IUD);

          -  Double barrier methods (such as condoms and spermicide); OR female subject must be
             postmenopausal for at least 12 months prior to trial entry or surgically sterile (i.e.
             hysterectomy, bilateral oophorectomy or bilateral tubal ligation).

          -  II 08: Subject covered by social security or covered by similar system.

          -  II 09: Subject, upon briefing of the content of the present study, fully understanding
             and agreeing to its objective; and being able to personally sign a written informed
             consent.

          -  II 10: Subject having given written (dated and signed) inform consent to take part in
             the study.

          -  II 11: Asian subjects originating from Japan

          -  II12: Subject who is able to communicate well with the investigator and to comply with
             the requirements of the entire study.

          -  II13: Subject having a fridge at home for study products storage with sufficient
             capacity.

        To be checked at the randomization visit (V2):

        - RI 01: Subject having followed the dietary recommendations over the wash-out period.

        Exclusion Criteria:

          -  To be checked at the inclusion visit (V1):

          -  IE 01: Subject having experienced any cardiovascular event (cardiac infarction, angina
             attack, surgical or endoscopic coronary angioplasty, stroke, arterial disease, etc.).

          -  IE 02: Subject suffering from any serious or chronic liver, renal, cardiovascular,
             respiratory, endocrine or metabolic disorders.

          -  IE 03: Subject with gastro-intestinal disorders (such as diarrhoea, constipation,
             irritable bowel syndrome) or using laxatives.

          -  IE 04: Subject with diabetes Type I and Type II or Fasting Blood Sugar test (FBS) &gt;
             125 mg/dL at screening visit.

          -  IE 05: Subject with active liver disease or hepatic dysfunction as defined by
             elevations in liver enzymes: [alanine aminotransferase (ALT), aspartate
             aminotransferase (AST), gamma glutamyl transferase (GGT) &gt; 3X the upper limit of
             normal (ULN).

          -  IE 06: Subject with unexplained serum creatine phosphokinase (CPK) &gt; 2X the upper
             limit of normal (ULN). Subject with a reason for CPK elevation may continue in
             inclusion process and have the measurement repeated prior to randomization; a repeat
             CPK &gt; 2X ULN is exclusionary.

          -  IE 07: Subject with weight change (variation &gt; 5%) within 6 months at least prior to
             inclusion.

          -  IE 08: Subject taking any hypocholesterolemic drugs or products (statins, ezetimibe,
             sequesterants, niacin, nicotinates, probucol, omega-3 fatty acids (EPA-DHA, ALAâ€¦), and
             fibrates).

          -  IE 09: Subjects having stopped their hypocholesterolemic drugs or products for less
             than 3 months

          -  IE 10: Subject with known lactose intolerance.

          -  IE 11: Subject with known allergy or hypersensitivity to plant sterols and to any
             component of the study product (milk protein for example).

          -  IE 12: Subjects having sitosterolemia.

          -  IE 13: Subject who had any surgery or intervention requiring a general anaesthesia in
             the preceding 4 weeks, or who plans to have one during the course of the study.

          -  IE 14: Subject receiving (currently or in the 4 last weeks) systemic treatment or
             topical treatment likely to interfere with evaluation of the study parameters.

          -  IE 15: Subject involved in any other clinical study within the preceding month or in
             the exclusion period after another clinical study.

          -  IE 16 Subject having blood sample of 200 mL or more taken (e.g., donated blood) within
             1 month, or 400 mL or more within 3 months before the start of the present study.

          -  IE 17: Subject with heavy alcohol intake (&gt; 60 g/day).

          -  IE 18: Subject taking any treatment for anorexia, weight loss, or any form of
             treatment likely to interfere with metabolism or dietary habits (e.g. hypolipemic,
             hypoglycaemic treatments).

          -  IE 19: For female subject: pregnant woman or woman planning to become pregnant during
             the study; breast-feeding woman.

          -  IE 20: For female subject: subject likely to change her contraceptive method or
             hormone replacement therapy during the study.

          -  IE 21: Subject in a situation, which in the investigator's opinion could interfere
             with optimal participation in the present study (e.g. -products consumer) or could
             constitute a special risk for the subject.

          -  IE 22: Subject who is susceptible to not comply with dietary qualitative restriction
             during the study period.

          -  IE 23 Vulnerable subjects defined as individuals whose willingness to volunteer in the
             clinical trial may be unduly influenced by the expectation, whether justified or not,
             of benefits associated with participation, or of a retaliatory response from senior
             members of a hierarchy in case of refusal to participate. Examples are members of a
             group with a hierarchical structure, such as medical, pharmacy, dental and nursing
             students, subordinate hospital and laboratory personnel, employees of the
             pharmaceutical industry, members of the armed forces, and persons kept in detention.

          -  IE 24: Subject expected to be living in the same home as a current participating
             subject and to concomitantly receive some study products.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine MRINI, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Danone Research Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yaesu Sakura-dori Clinic</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>October 29, 2014</last_update_submitted>
  <last_update_submitted_qc>October 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese healthy volunteers</keyword>
  <keyword>High LDL-C</keyword>
  <keyword>dairy drinks</keyword>
  <keyword>phytosterols</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

